Spontaneous Bacterial Peritonitis in an Adult Patient with Minimal Change Disease

Background: Pediatric patients with nephrotic syndrome have a high risk of developing spontaneous bacterial peritonitis (SBP). However, SBP in adults with nephrotic syndrome is very rare. We report a case of SBP induced by *Escherichia coli* in a 60-year-old male patient on immunosuppressive therapy for the treatment of minimal change disease (MCD).

Case Report: The patient was hospitalized with abdominal pain and generalized edema that had lasted for 2 weeks. The patient first started treatment with high-dose oral prednisolone after being diagnosed with MCD 6 months ago. Complete remission of nephrotic syndrome was not achieved even after 5 months of treatment. Thus, the treatment was changed to combination therapy with cyclosporine and low-dose prednisolone. At the time of admission, leukocytosis, hypoalbuminemia, decreased serum immunoglobulin G (IgG), azotemia, and nephrotic-range proteinuria were observed. Ascitic fluid analysis showed a leukocyte count of 4960/μL (neutrophils 90%). On the suspicion of SBP associated with MCD, intravenous administration of empirical cefotaxime and supportive therapy were initiated; however, symptoms of peritonitis persisted. Extended-spectrum beta-lactamase-negative *E. coli* was found in ascites cultures. Laparoscopy-assisted peritoneal biopsy revealed no evidence of fungal infection; however, chronic inflammation without granuloma formation was noted. Afterward, cefotaxime was changed to piperacillin-tazobactam. After 4 weeks of antibacterial therapy, the peritonitis was cured and renal function was improved.

Conclusions: Adult patients with steroid-resistant MCD accompanied by refractory ascites, severe hypoalbuminemia, and marked reduction in serum IgG are at a high risk of subsequent SBP and require careful monitoring.

Keywords: Nephrosis, Lipoid • Nephrotic Syndrome • Peritonitis

Full-text PDF: https://www.amjcaserep.com/abstract/index/idArt/930677
Background

In patients with nephrotic syndrome, urinary excretion of proteins such as immunoglobulins and complement factors is increased, and the risk of infection increases due to complications such as lymphocyte dysfunction, administration of immunosuppressive agents, ascites, and edema [1]. The most common infectious complications include pneumonia, sepsis, cellulitis, and spontaneous bacterial peritonitis (SBP) [2]. SBP is a disease in which peritoneal bacterial inflammation occurs without apparent clinical evidence of infections in the abdominal cavity such as perforation of intraperitoneal organs, abscess, acute pancreatitis, or cholecystitis [3]. SBP is the most common infection in patients with advanced liver cirrhosis [3]. In addition, SBP is mainly observed in pediatric patients with nephrotic syndrome, and ascites predisposes to SBP development. Once developed, SBP greatly increases the rates of morbidity and mortality [2]. SBP is relatively rare in adult patients with nephrotic syndrome compared to pediatric patients with nephrotic syndrome. Thus, there are only sporadic reports on adults to date [4-9].

We report a case of extended-spectrum beta-lactamase (ESBL)-negative Escherichia coli-induced SBP in a 60-year-old male patient on immunosuppressive agents for minimal change disease (MCD), and review the pertinent literature.

Case Report

A 60-year-old man presented to the division of nephrology with chief complaints of abdominal pain and generalized edema, which had started 2 weeks earlier. The patient underwent a renal biopsy for nephrotic syndrome 6 months prior to the visit and was diagnosed with MCD (Figure 1A, 1B). Serum biochemistry at that time revealed a blood urea nitrogen (BUN) of 23.1 mg/dL, creatinine (Cr) 0.8 mg/dL, albumin 1.9 g/dL, and total cholesterol 371 mg/dL. The spot urine protein-to-Cr ratio was 8.864 g/g at that time. In the serum immunological tests, immunoglobulin G (IgG) level was decreased to 487 mg/dL (reference range, 700-1600 mg/dL); however, IgA and IgM levels were within the normal range. The concentrations of complement (C) 3 and C4 were within the normal range as well. Anti-streptolysin O, Venereal Disease Research Laboratory (VDRL) test, HBS Ag, and anti-HCV, anti-HIV, anti-nuclear, and anti-double stranded DNA antibodies were all negative. After MCD diagnosis, the patient started high-dose steroid therapy with oral prednisolone (60 mg/day, 1 mg/kg per day). However, complete remission was not achieved, and as generalized edema persisted even after 5 months of oral corticosteroids, steroid-resistant MCD was presumed. Therefore, 1 month prior to presentation, the treatment was changed to cyclosporine (300 mg/day, 5 mg/kg per day) in combination with low-dose oral prednisolone (10 mg/day).

At the time of admission, blood pressure, pulse rate, respiratory rate, and body temperature were 140/90 mmHg, 64/min, 21/min, and 37.8ºC, respectively. The patient was conscious but had an acutely ill appearance. He had no history of hypertension, diabetes mellitus, or liver or cardiac diseases. Abdominal examination showed marked distension of the abdomen with no hepatosplenomegaly. Diffuse tenderness, but no rebound tenderness, was noted. Moderate pitting edema was present in both lower extremities. A peripheral blood test showed a white blood cell (WBC) count of 13 700/μL (neutrophils 94.5%), hemoglobin 13.1 g/dL, platelet count 245 000/μL; and erythrocyte sedimentation rate 96 mm/h. Serum biochemical examination revealed BUN 104 mg/dL, Cr, 3.2 mg/dL (estimated

Figure 1. Microscopic features of kidney biopsy. (A) Glomeruli appear unremarkable, and there are no specific vascular or tubulointerstitial lesions (methenamine silver stain, ×400). (B) Foot process effacement is extensive. The glomerular basement membrane is unremarkable, and there are no electron-dense deposits (transmission electron microscope, ×4000).
glomerular filtration rate 20 mL/min/1.73 m², total protein 4.4 g/dL, albumin 1.7 g/dL, total cholesterol 753 mg/dL, and C-reactive protein (CRP) 68.1 mg/L (reference range <5 mg/L). Urinalysis with microscopic examination showed albumin 3+, a WBC count of 5-9/high-power field (HPF), and a red blood cell (RBC) count of 10-30/HPF (90% dysmorphic). The spot urine protein-to-Cr ratio was 6.998 g/g. Serum IgG concentration was significantly reduced to 420 mg/dL. Abdominal computed tomography revealed no abnormality except massive ascites and intestinal wall edema. Paracentesis showed cloudy ascites, and ascitic fluid analysis showed WBC of 4960/μL (neutrophils 90%), RBC 720/μL, and lactate dehydrogenase 341 IU/L. As SBP was suspected, ascites was drained, and an empirical broad-spectrum antibiotic (cefotaxime) was administered intravenously (2.0 g, 2×/day).

On the fifth hospital day, ESBL-negative E. coli was isolated from the ascites culture. No bacteria were detected in blood cultures. On hospital day 10, abdominal pain and low-grade fever persisted, and peritonitis signs continued with a WBC count of 2464/μL in the ascitic fluid. The antibiotic was changed to intravenous piperacillin-tazobactam (4.5 g 3×/day), and laparoscopy-assisted peritoneal biopsy was performed. In the peritoneum, chronic inflammation was noted without formation of granulomas (Figure 2A, 2B), and acid-fast bacilli (AFB) staining and AFB polymerase chain reaction results were negative. The abdominal pain and distended abdomen gradually improved after the administration of alternative antibiotics, and WBC counts in the ascites stayed at a reduced level (<10/μL). Bacteria were no longer detected in repeated cultures of ascites. Antibiotics were administered for a total of 4 weeks during hospitalization. On the 30th hospital day, the patient was discharged with a serum albumin level of 1.9 g/dL, Cr 0.8 mg/dL, and CRP 5.1 mg/L. No recurrence of peritonitis was observed for 12 months after discharge. The patient is currently being followed up with the administration of immunosuppressive agents (cyclosporine and low-dose oral prednisolone) and angiotensin-converting enzyme inhibitor.

Discussion

SBP is one of the major complications in pediatric patients under the age of 10 years with nephrotic syndrome [2]. Indicators of SBP include an absence of infectious lesions in the peritoneal cavity requiring surgical treatment and neutrophils >250/μL in the ascites [3]. The incidence rate of SBP is 2-6% in pediatric patients with nephrotic syndrome, and the mortality rate is reported to be 1.5% [2]. SBP usually occurs within 2 years after the diagnosis of nephrotic syndrome and rarely appears as the first symptom of nephrotic syndrome. However, SBP has been discovered as a complication at the time of recurrence of nephrotic syndrome [10,11].

SBP in adult patients (>18 years old) with nephrotic syndrome is very rare compared to pediatric patients. Since the report of the first case in 1978 [4], 14 cases have been reported in the English literature (Table 1). Our retrospective analysis of these cases shows a male-to-female ratio of 1.8:1 and a mean age of 36.6 years (range 20-56 years) at the time of diagnosis. Although there were 4 cases without pathological confirmation, MCD was the most common cause of nephrotic syndrome (5/14; 35.7%), followed by focal segmental glomerulosclerosis (2/14), amyloidosis (2/14), and membranoproliferative glomerulonephritis (1/14). SBP mostly occurred within 2 years of diagnosis of nephrotic syndrome, which was similar to the occurrence in pediatric patients. In particular, 5 cases (5/14; 35.7%) of peritonitis occurred simultaneously or within the first month of diagnosis of nephrotic syndrome [6,7]. Streptococcus pneumoniae and E. coli were the 2 most commonly isolated causative pathogens,
Table 1. Cases of spontaneous bacterial peritonitis in adult patients with nephrotic syndrome.

| Year reported | Age (years)/ Gender | Renal pathology | Duration* (months) | Causative microorganism | Immuno-suppressants | BUN/Cr (mg/dL) | SA (g/dL) | Antibiotic therapy | Clinical outcome |
|---------------|---------------------|-----------------|--------------------|-------------------------|---------------------|----------------|-----------|-------------------|-----------------|
| 1978 [4]      | 41/F                | FSGS            | 2 years            | Hemophilus influenzae   | None                | NR             | 1.2       | Ampicillin        | Cure            |
| 1993 [5]      | 25/M                | FSGS            | 15 years           | Citrobacter freundii    | None                | 53.5/6.0       | 1.8       | IMP/TM           | Cure            |
| 1999 [6]      | 28/F                | MPGN            | 0                  | S. pneumoniae           | None                | 28/3.1         | 2.2       | CP/Oxacillin      | Cure            |
| 1999 [7]      | 20/M                | MCD             | 2 years            | S. viridans             | PDL                 | 51/3.2         | 1.3       | NR               | Cure            |
| 1999 [7]      | 32/M                | MCD             | 1 year             | No growth               | PDL                 | 24/1.8         | 1.4       | NR               | Cure            |
| 1999 [7]      | 48/M                | No biopsy       | 3                  | Aeromonas sobria        | PDL                 | 16/1.2         | 1.4       | NR               | Cure            |
| 1999 [7]      | 56/M                | No biopsy       | 0                  | Acinetobacter           | None                | 10/0.7         | 1.2       | NR               | Cure            |
| 1999 [7]      | 45/F                | MCD             | 0                  | Escherichia coli        | None                | 39/1.4         | 0.7       | NR               | Cure            |
| 1999 [7]      | 49/M                | No biopsy       | 0                  | Klebsiella pneumoniae   | PDL                 | 91/2.5         | 1.6       | Death            |
| 1999 [7]      | 25/M                | MCD             | 5                  | Escherichia coli        | CYP+CYS             | 28/1.5         | 2.3       | NR               | Death           |
| 1999 [7]      | 29/M                | No biopsy       | 0                  | No growth               | None                | 183/7.4        | 1.9       | NR               | Death           |
| 2005 [8]      | 38/F                | AA amyloidosis  | 1 year             | No growth               | None                | 47.3/5.6       | 1.3       | Cefotaxime        | Cure            |
| 2005 [8]      | 30/F                | AA amyloidosis  | 8                  | No growth               | Methyl-PDL          | 82.9/5.7       | 1.4       | Cefotaxime        | Cure            |
| 2018 [9]      | 46/M                | MCD             | NR                 | S. pneumoniae           | PDL+CYS             | 56.3/4.6       | <1.0      | PC/Cloxacillin    | Cure            |
| Our case      | 60/M                | MCD             | 6                  | Escherichia coli        | PDL+CYS             | 104/3.2        | 1.7       | Cefotaxime/PT     | Cure            |

* Duration of nephrotic syndrome prior to occurrence of spontaneous bacterial peritonitis. BUN – blood urea nitrogen; Cr – serum creatinine; SA – serum albumin; F – Female; M – Male; FSGS – focal segmental glomerulosclerosis; MPGN – membranoproliferative glomerulonephritis; MCD – minimal change disease; NR – not reported; S – Streptococcus; CYP – cyclophosphamide; CYS – cyclosporine; PDL – prednisolone; IMP – imipenem; TM – tobramycin; PC – penicillin-G; PT – piperacillin-tazobactam.

with 2 cases each; however, there were also 4 cases in which the causative microorganisms were not detected in ascites cultures. Azotemia was present in most patients (11/13; 84.6%), and the mean serum BUN and Cr levels of the patients were 53.9±42.9 mg/dL and 3.4±2.1 mg/dL, respectively. Furthermore, severe hypoalbuminemia (<2.0 g/dL) was observed in most patients (13/14; 93%) (Table 1). This patient, a 60-year-old man, was older than previously reported patients, and E. coli-induced SBP developed 6 months after MCD diagnosis. The patient was presumed to be suffering from steroid-resistant MCD, as the symptoms and laboratory data associated with nephrotic syndrome were not improved even after high-dose oral prednisolone therapy [12]. Subsequently, peritonitis developed during combined therapy with cyclosporine and low-dose prednisolone.

SBP occurrence in patients with nephrotic syndrome is associated with a number of risk factors [6]. In patients with nephrotic syndrome, serum opsonic activity and phagocytosis of encapsulated microorganisms decrease due to the decreased levels of serum IgG and complement factors B and D [13,14]. In addition, T-lymphocyte dysfunction increases the susceptibility to bacterial infections [15]. Hypoalbuminemia leads to a secondary increase in ascites production and a diluent decrease in the concentration of complements and immunoglobulins in the ascites, thereby reducing bacterial activity in the peritoneal cavity. Moreover, bowel wall edema and venous congestion of the gastrointestinal tract may facilitate intraperitoneal permeation of intestinal bacteria [16,17]. The administration of immunosuppressive agents for the treatment of nephrotic syndrome is also suggested as a major factor in the development of peritonitis. Among previous cases of adult nephrotic syndrome, 6 patients (6/14; 42.8%) were on immunosuppressive therapy at the time of SBP onset, and 5 of these 6 patients were being treated with corticosteroids (Table 1). However, a study reported that only 50% of pediatric patients with nephrotic syndrome and SBP were on steroid therapy when diagnosed with peritonitis [18]. Therefore, the clinical association between the administration of immunosuppressive agents and SBP is not yet established.

The most common bacterial species that cause SBP in pediatric nephrotic patients include S. pneumoniae and Gram-negative...
bacteria, particularly *E. coli* [11]. In the adult cases of peritonitis complicated with nephrotic syndrome, *E. coli* and *S. pneumoniae* were also the most common causative pathogens, followed by Gram-negative bacteria, which showed a higher frequency than Gram-positive bacteria (Table 1). Treatment of SBP requires empirical administration of antibiotics before the results of ascitic fluid and/or blood cultures and antibiotic susceptibility tests are available. Third-generation ceph- alosporins (eg, cefotaxime, ceftriaxone), which are effective against most causative bacteria such as *E. coli*, *K. pneumoniae*, and *Streptococcus*, are recommended [3]. Since the recurrence rate of peritonitis is high in patients with liver cirrhosis and ascites, especially in high-risk groups, administration of norfloxacin or rifaximin is used as primary or secondary prophylaxis against SBP [3,19]. The prevalence and recurrence rate of SBP in adult patients with nephrotic syndrome are not yet clear. Therefore, further studies are needed to determine whether this prophylactic therapy against SBP in the patients with liver cirrhosis can be applied to those with nephrotic syndrome.

It is also unclear why SBP is more common in pediatric patients with nephrotic syndrome than in adults. Possible clinical explanations include that MCD, in which cellular and humoral immune systems are markedly impaired, is more common in children, and ascites formation along with severe hypoalbuminemia is more pronounced in pediatric nephrotic syndrome [6]. In a study comparing the clinical characteristics of 52 adults and 21 children with nephrotic syndrome, ascites was observed in 23% and 52%, respectively, and the mean serum albumin concentration was significantly lower in pediatric patients with ascites than in adult patients with ascites (1.7 g/dL vs 2.1 g/dL) [17]. Furthermore, in adults with nephrotic syndrome, congestive heart failure and chronic liver disease, which lead to an increase in hepatic sinusoidal pressure in addition to hypoalbuminemia, may increase ascites production [17]. A marked decrease in serum albumin (<1.5 g/dL) is known as a significant risk factor predicting the development of SBP in patients with nephrotic syndrome. However, the classic markers indicative of active renal diseases, such as hypertension and microscopic hematuria, were not associated with the occurrence of peritonitis [10]. This may suggest that the incidence of SBP associated with nephrotic syndrome can be reduced if clinical remission is achieved with optimal treatment. In our analysis of published cases of adult nephrotic syndrome with SBP, renal dysfunction (serum Cr >1.4 mg/dL) and severe hypoalbuminemia (serum albumin <2.0 g/dL) were present in most patients (Table 1).

Azotemia accompanied by SBP development is presumed to be related to prerenal acute kidney injury caused by hypoalbuminemia and/or endogenous renal insufficiency secondary to intraabdominal inflammation. Renal dysfunction was actually improved to the normal level in most patients after cure of SBP. However, 1 case of irreversible renal failure even after amelioration of SBP with antibiotic therapy [5] and 3 cases of in-hospital mortality from septic shock during peritonitis treatments have been reported [7]. Therefore, prompt and appropriate treatment and careful follow-up are needed on suspicion of SBP. Significantly reduced serum IgG (<600 mg/dL) and renal insufficiency (serum Cr >2.0 mg/dL) were reported as independent risk factors for the development of bacterial infection in adult patients with nephrotic syndrome [20]. In our case, congestive heart failure and chronic liver disease were not identified in the patient, and there were no localized infections or other clinical evidence suggestive of secondary peritonitis. Therefore, it can be inferred that the decrease in serum albumin (1.7 g/dL), low serum IgG (420 mg/dL), and renal dysfunction were significantly associated with the development and persistence of SBP.

**Conclusions**

This case report describes an adult MCD patient who developed *E. coli*-induced SBP while on immunosuppressive therapy with cyclosporine and oral prednisolone. Peritonitis was cured with intravenous administration of broad-spectrum antibiotics. As this case demonstrates, steroid-resistant MCD patients with refractory ascites, severe hypoalbuminemia, and a prominent decrease in serum IgG concentration have a high risk of developing subsequent SBP and require cautious monitoring and follow-up. Furthermore, when peritonitis occurs, rapid antibiotic administration and appropriate supportive therapy are critical to prevent secondary complications such as permanent renal injury and sepsis. Further study is required to clarify the association between the administration of immunosuppressive agents and SBP.

**Conflict of Interest**

None.
References:

1. Wang CS, Greenbaum LA. Nephrotic syndrome. Pediatr Clin North Am. 2019;66(1):73-85
2. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629-39
3. Dever JB, Sheikh MY. Review article: Spontaneous bacterial peritonitis – bacteriology, diagnosis, treatment, risk factors and prevention. Aliment Pharmacol Ther. 2015;41(11):1116-31
4. Rusthoven J, Kabins SA. Hemophilus influenzae f cellulitis with bacteremia, peritonitis, and pleuritis in an adult with nephrotic syndrome. South Med J. 1978;71(11):433-35
5. Kato A, Ohtake T, Furuya R, et al. Spontaneous bacterial peritonitis in an adult patient with nephrotic syndrome. Intern Med. 1993;32(9):719-21
6. Chuang TF, Kao SC, Tsai CJ, et al. Spontaneous bacterial peritonitis as the resenting feature in an adult with nephrotic syndrome. Nephrol Dial Transplant. 1999;14(1):181-82
7. Chen MC, Lam KK, Hsu KT. Spontaneous bacterial peritonitis in adult patients with primary nephrotic syndrome. Changgeng Yi Xue Za Zhi. 1999;22(2):227-33
8. Danis R, Ozmen S, Yilmaz S, et al. Adult nephrotic syndrome with spontaneous bacterial peritonitis: A case report. Clin Nephrol. 2018;90(1):76-78
9. Hingorani SR, Weiss NS, Watkins SL. Predictors of peritonitis in children with nephrotic syndrome. Pediatr Nephrol. 2002;17(8):678-82
10. Uncu N, Bülbül M, Yildiz N, et al. Primary peritonitis in children with nephrotic syndrome: Results of a 5-year multicenter study. Eur J Pediatr. 2010;169(3):73-76
11. Vivarelli M, Massella L, Ruggiero B, et al. Minimal change disease. Clin J Am Soc Nephrol. 2017;12(2):332-45
12. Yokoyama H, Kida H, Abe T, et al. Impaired immunoglobulin G production in minimal change nephrotic syndrome in adults. Clin Exp Immunol. 1987;70(1):110-15
13. Matsell D, Wyatt RJ. The role of I and B in peritonitis associated with the nephrotic syndrome. Pediatr Res. 1993;34(1):84-88
14. Goonwaedene ST, Tang C, Tan LT, et al. Safety and efficacy of pneumococcal vaccination in pediatric nephrotic syndrome. Fron Pediatr. 2019;11(7):339
15. Akalin HE, Fisher KA, Lalelli Y, et al. Bactericidal activity of ascitic fluid in patients with nephrotic syndrome. Eur J Clin Invest. 1985;15(3):138-40
16.ACKERMAN Z. Ascites in nephrotic syndrome: Incidence, patient’s characteristics, and complications. J Clin Gastroenterol. 1996;22(1):31-34
17. Feinstein EI, Chesney RW, Zelikovic I. Peritonitis in childhood renal disease. Am J Nephrol. 1988;8(2):147-65
18. Soni H, Kumar-M P, Sharma V, et al. Antibiotics for prophylaxis of spontaneous bacterial peritonitis: Systemic review & Bayesian network meta-analysis. Hepatol Int. 2020;14(3):399-413
19. Ogi M, Yokoyama H, Tomosugi N, et al. Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome. Am J Kidney Dis. 1994;24(3):427-36